Public Act 0091 97TH GENERAL ASSEMBLY |
Public Act 097-0091 |
HB1191 Enrolled | LRB097 06572 RPM 46657 b |
|
|
AN ACT concerning insurance.
|
Be it enacted by the People of the State of Illinois, |
represented in the General Assembly:
|
Section 5. The Illinois Insurance Code is amended by |
changing Sections 356z.16 and 364.01 as follows: |
(215 ILCS 5/356z.16) |
Sec. 356z.16. Applicability of mandated benefits to |
supplemental policies. Unless specified otherwise, the |
following Sections of the Illinois Insurance Code do not apply |
to short-term travel, disability income, long-term care, |
accident only, or limited or specified disease policies: 356b, |
356c, 356d, 356g, 356k, 356m, 356n, 356p, 356q, 356r, 356t, |
356u, 356w, 356x, 356z.1, 356z.2, 356z.4, 356z.5, 356z.6, |
356z.8, 356z.12, 364.01, 367.2-5, and 367e.
|
(Source: P.A. 96-180, eff. 1-1-10; 96-1000, eff. 7-2-10; |
96-1034, eff. 1-1-11.) |
(215 ILCS 5/364.01) |
Sec. 364.01. Qualified clinical cancer trials. |
(a) No individual or group policy of accident and health |
insurance issued or renewed in this State may be cancelled or |
non-renewed for any individual based on that individual's |
participation in a qualified clinical cancer trial. |
|
(b) Qualified clinical cancer trials must meet the |
following criteria: |
(1) the effectiveness of the treatment has not been |
determined relative to established therapies; |
(2) the trial is under clinical investigation as part |
of an approved cancer research trial in Phase II, Phase |
III, or Phase IV of investigation; |
(3) the trial is: |
(A) approved by the Food and Drug Administration; |
or |
(B) approved and funded by the National Institutes |
of Health, the Centers for Disease Control and |
Prevention, the Agency for Healthcare Research and |
Quality, the United States Department of Defense, the |
United States Department of Veterans Affairs, or the |
United States Department of Energy in the form of an |
investigational new drug application, or a cooperative |
group or center of any entity described in this |
subdivision (B); and
|
(4) the patient's primary care physician, if any, is |
involved in the coordination of care.
|
(c) No group policy of accident and health insurance shall |
exclude coverage for any routine patient care administered to |
an insured who is a qualified individual participating in a |
qualified clinical cancer trial, if the policy covers that same |
routine patient care of insureds not enrolled in a qualified |
|
clinical cancer trial. |
(d) The coverage that may not be excluded under subsection |
(c) of this Section is subject to all terms, conditions, |
restrictions, exclusions, and limitations that apply to the |
same routine patient care received by an insured not enrolled |
in a qualified clinical cancer trial, including the application |
of any authorization requirement, utilization review, or |
medical management practices. The insured or enrollee shall |
incur no greater out-of-pocket liability than had the insured |
or enrollee not enrolled in a qualified clinical cancer trial. |
(e) If the group policy of accident and health insurance |
uses a preferred provider program and a preferred provider |
provides routine patient care in connection with a qualified |
clinical cancer trial, then the insurer may require the insured |
to use the preferred provider if the preferred provider agrees |
to provide to the insured that routine patient care. |
(f) A qualified clinical cancer trial may not pay or refuse |
to pay for routine patient care of an individual participating |
in the trial, based in whole or in part on the person's having |
or not having coverage for routine patient care under a group |
policy of accident and health insurance. |
(g) Nothing in this Section shall be construed to limit an |
insurer's coverage with respect to clinical trials. |
(h) Nothing in this Section shall require coverage for |
out-of-network services where the underlying health benefit |
plan does not provide coverage for out-of-network services. |
|
(i) As used in this Section, "routine patient care" means |
all health care services provided in the qualified clinical |
cancer trial that are otherwise generally covered under the |
policy if those items or services were not provided in |
connection with a qualified clinical cancer trial consistent |
with the standard of care for the treatment of cancer, |
including the type and frequency of any diagnostic modality, |
that a provider typically provides to a cancer patient who is |
not enrolled in a qualified clinical cancer trial. "Routine |
patient care" does not include, and a group policy of accident |
and health insurance may exclude, coverage for: |
(1) a health care service, item, or drug that is the |
subject of the cancer clinical trial; |
(2) a health care service, item, or drug provided |
solely to satisfy data collection and analysis needs for |
the qualified clinical cancer trial that is not used in the |
direct clinical management of the patient; |
(3) an investigational drug or device that has not been |
approved for market by the United States Food and Drug |
Administration; |
(4) transportation, lodging, food, or other expenses |
for the patient or a family member or companion of the |
patient that are associated with the travel to or from a |
facility providing the qualified clinical cancer trial, |
unless the policy covers these expenses for a cancer |
patient who is not enrolled in a qualified clinical cancer |
|
trial; |
(5) a health care service, item, or drug customarily |
provided by the qualified clinical cancer trial sponsors |
free of charge for any patient; |
(6) a health care service or item, which except for the |
fact that it is being provided in a qualified clinical |
cancer trial, is otherwise specifically excluded from |
coverage under the insured's policy, including: |
(A) costs of extra treatments, services, |
procedures, tests, or drugs that would not be performed |
or administered except for the fact that the insured is |
participating in the cancer clinical trial; and |
(B) costs of nonhealth care services that the |
patient is required to receive as a result of |
participation in the approved cancer clinical trial; |
(7) costs for services, items, or drugs that are |
eligible for reimbursement from a source other than a |
patient's contract or policy providing for third-party |
payment or prepayment of health or medical expenses, |
including the sponsor of the approved cancer clinical |
trial; or |
(8) costs associated with approved cancer clinical |
trials designed exclusively to test toxicity or disease |
pathophysiology, unless the policy covers these expenses |
for a cancer patient who is not enrolled in a qualified |
clinical cancer trial; or |
|
(9) a health care service or item that is eligible for |
reimbursement by a source other than the insured's policy, |
including the sponsor of the qualified clinical cancer |
trial. |
The definitions of the terms "health care services", |
"Non-Preferred Provider", "Preferred Provider", and "Preferred |
Provider Program", stated in 50 IL Adm. Code Part 2051 |
Preferred Provider Programs apply to these terms in this |
Section. |
(j) The external review procedures established under the |
Health Carrier External Review Act shall apply to the |
provisions under this Section. |
(Source: P.A. 93-1000, eff. 1-1-05.)
|
Section 99. Effective date. This Act takes effect January |
1, 2012.
|